Acadia Pharmaceuticals (ACAD) Depreciation and Depletion (2010 - 2026)

Acadia Pharmaceuticals' Depreciation and Depletion history runs 17 years deep, the most recent figure standing at $271000.0 for Q1 2026.

• On a quarterly basis, Depreciation and Depletion rose 18.34% year-over-year to $271000.0 in Q1 2026; TTM through Mar 2026 was $942000.0, a 6.2% increase from a year earlier, with the FY2025 full-year figure at $900000.0, changed 0.0% from the prior year.
• Depreciation and Depletion grew to $271000.0 in Q1 2026 per ACAD's latest filing, from $231000.0 in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $516000.0 in Q1 2022 and bottomed at $206000.0 in Q4 2024.
• The 5-year median for Depreciation and Depletion is $271000.0 (2026), against an average of $325294.1.
• Across the five-year window, Depreciation and Depletion tumbled 43.78% in 2024 and gained 18.34% in 2026, its largest moves.
• Year by year, Depreciation and Depletion stood at $463000.0 in 2022, then slumped by 41.25% to $272000.0 in 2023, then fell by 24.26% to $206000.0 in 2024, then gained by 12.14% to $231000.0 in 2025, then grew by 17.32% to $271000.0 in 2026.
• Per Business Quant, the three latest ACAD Depreciation and Depletion figures stand at $271000.0 (Q1 2026), $231000.0 (Q4 2025), and $227000.0 (Q3 2025).